Skip to main content
Clinical Trials/NCT04713501
NCT04713501
Completed
Not Applicable

Program for Alleviating and Resolving Trauma and Stress Study (Stage 1 Pilot)

Cambridge Health Alliance1 site in 1 country15 target enrollmentDecember 22, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post-traumatic Stress Disorder
Sponsor
Cambridge Health Alliance
Enrollment
15
Locations
1
Primary Endpoint
Change from Baseline CAPS-5 at 16 Weeks
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This single-arm pilot study (Phase 1) will test the preliminary efficacy of a virtually delivered, live-online 16-week group model of Internal Family Systems (IFS) for individuals with PTSD, called the PARTS program, on PTSD symptoms measured by Clinician-Administered PTSD Scale (CAPS-5). In addition, feasibility, acceptability, and effects on self-report PTSD and disturbances of self-organization (DSO) will be secondary outcomes.

Detailed Description

The investigators will conduct a single-arm pilot study to test the preliminary efficacy of a virtually delivered, live-online 16-week group model of Internal Family Systems (IFS) for individuals with PTSD, called the PARTS program, on PTSD symptoms measured by Clinician-Administered PTSD Scale (CAPS-5). Secondary outcomes include feasibility and acceptability of the PARTS program measured by a Credibility/Expectancy Questionnaire (CEQ) and Treatment Satisfaction Questionnaire. Secondary clinical outcomes include the effects of the PARTS program on self-report PTSD and disturbances of self-organization (DSO). Exploratory aims of the study are to investigate the effects on emotion regulation (DERS), self-trauma fusion (iPRISM-trauma), disassociation (MDI), depression (CAT-DI), self-compassion (SCS-SF), perceived stress (PSS), mindfulness (TMS), and interception (MAIA-2). Additional exploratory outcomes include changes in outcome variables among PTSD subjects with baseline DSO and those without DSO as defined by the International Trauma Questionnaire (ITQ).

Registry
clinicaltrials.gov
Start Date
December 22, 2020
End Date
July 31, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zev Schuman Olivier

Assistant Professor, Psychiatry

Cambridge Health Alliance

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change from Baseline CAPS-5 at 16 Weeks

Time Frame: Week 16

The primary aim of this study is to examine the preliminary efficacy of a live-online version of the PARTS program on PTSD symptoms measured by reduction in CAPS-5 over 24 weeks. The CAPS-5 is a 30-item questionnaire administered by a trained interviewer and is considered the "gold standard" assessment for PTSD diagnosis and symptoms as defined by the DSM-5. This measure also assesses the duration of symptoms, impact of symptoms on aspects of the participant's life, and if the participant meets criteria for the dissociative subtype of PTSD.

Secondary Outcomes

  • Acceptability as assessed by Satisfaction Survey(Week 16)
  • Change from Baseline Self-reported PTSD symptoms (CAT-PTSD) at 16 Weeks(Week 16)
  • Retention(Week 16)
  • Change from Baseline Self-reported PTSD symptoms (PCL-5) at 16 Weeks(Week 16)
  • Change from Baseline Disturbances of Self Organization -- International Trauma Questionnaire (ITQ-DSO-9) at 16 Weeks(Week 16)

Study Sites (1)

Loading locations...

Similar Trials